Earnings Summary

Inovio Pharmaceuticals, Inc.’s revenue fell -95.76% since last year same period to $0.39Mn in the Q3 2023. On a quarterly growth basis, Inovio Pharmaceuticals, Inc. has generated 71.9% jump in its revenue since last 3-months.

Inovio Pharmaceuticals, Inc.’s net profit jumped 14.36% since last year same period to $-33.93Mn in the Q3 2023. On a quarterly growth basis, Inovio Pharmaceuticals, Inc. has generated 4.52% jump in its net profits since last 3-months.

Inovio Pharmaceuticals, Inc.’s net profit margin fell -1918.3% since last year same period to -8734.77% in the Q3 2023. On a quarterly growth basis, Inovio Pharmaceuticals, Inc. has generated 44.45% jump in its net profit margins since last 3-months.

Inovio Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.11 - a 15.38% jump from last quarter’s estimates.

Inovio Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.11.

Inovio Pharmaceuticals, Inc.’s earning per share (EPS) jumped 13.33% since last year same period to -0.13 in the Q3 2023. This indicates that the Inovio Pharmaceuticals, Inc. has generated 13.33% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Inovio Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.35.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Inovio Pharmaceuticals, Inc.’s return on equity (ROE) stands at -0.81.